By the end of the month, the Ohio State University James Cancer Hospital will open a Phase 2 clinical trial to test two drugs for the treatment of triple negative breast cancer -- a very aggressive type of cancer with high rates of recurrence. The trial, developed and led by oncologist Dr. Erin Macrae, will test two drugs that are taken together. Earlier this year the U.S. Food and Drug Administration approved one of the drugs, trafetinib, for the treatment of advanced melanoma. The other drug is a study drug. Both were developed by drug manufacturer GlaxoSmithKline. An earlier Phase 1 trial at another cancer center has already established that the drugs are safe to use in humans. This new trial is studying to see what effects, if any, the drugs have on patients and their cancer. This coverage resulted from pitching efforts by Ohio State University Wexner Medical Center Public Affairs and Media Relations.